Sun Pharmaceuticals Agrees to Pay $485 Million to Settle Antitrust Claims Against Ranbaxy
- March 25, 2022
Sun Pharmaceutical Industries Ltd. has agreed to pay $485 million to two plaintiffs groups—direct purchaser and end-payer—to resolve antitrust litigation against its U.S.-based subsidiary Ranbaxy, Inc.
ARTICLE TAGS
You must be logged in to access this content.